Search

Displaying results 791 - 800 of 3917 in total
  1. Drug

    Mesalazine

    go.drugbank.com/drugs/DB00244
    ApprovedInvestigational

    An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022].

    Categories: Analgesics, Non-NarcoticProducts: SULIMAX® 500 MG TABLETAS CON CUBIERTA ENTERICA, SALOFALK 250 MG TABLETAS CON RECUBRIMIENTO ENTERICO
  2. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

  3. Drug

    Guanfacine

    go.drugbank.com/drugs/DB01018
    ApprovedInvestigational

    [A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]

  4. Drug

    Arnica montana flower

    go.drugbank.com/drugs/DB14343
    Approved

    Arnica montana flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Joint Bone Care, Bee Venom Joint And Bone Therapy Drops
  5. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects.

    Products: VALCOTE® 250 MG TABLETAS CON CUBIERTA ENTÉRICA, ATEMPERATOR 500MG TABLETAS CON CUBIERTA ENTÉRICA
  6. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...

    Mixtures: GALVUS® MET 50/500 COMPRIMIDOS RECUBIERTOS CON PELICULA, GALVUS® MET COMPRIMIDO RECUBIERTO CON PELICULA 50 MG/850 MG
  7. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications previously only available via intravenous administration, including melanoma, non-small

  8. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

  9. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

  10. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively.